Incyte Corporation (INCY) · Insider trading

What Incyte's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.

Bought, 12 months

0 insiders, 0 trades

Sold, 12 months

$57.96M

10 insiders, 100% under a plan

Net, 12 months

−$57.96M

bought less sold

Latest filing

2026-10-05

filings read to 2026-10-19

Bought and sold at the market, by month

Two years. Purchases above the line, sales below, in dollars.

Bought Sold Largest month: $20.77M

Who traded, two years

Insider	Bought	Sold	Trades	Last trade	Holds after
Hoppenot HerveDirector	–	$19.77M	1	2025-11-10	329,646
Cagnoni Pablo JPresident, Global Head of R&D	–	$14.10M	9	2026-09-15	197,185
Stein Steven HCMO & Head of Late-Stage Dev.	–	$10.03M	9	2026-07-16	21,118
Mayes Patrick AEVP & Chief Scientific Officer	–	$6.56M	15	2026-08-05	61,441
Morrissey Michael JamesEVP, Head of Tech. Operations	–	$5.68M	3	2025-12-17	27,507
Flannelly Barry PEVP & General Manager US	–	$2.55M	8	2025-07-16	35,149
Denton Sheila A.EVP & General Counsel	–	$2.14M	16	2025-11-17	26,569
Clancy Paul JDirector	–	$1.42M	1	2026-05-19	23,741
Issa Mohamed KhairieEVP, Head of U.S. Commercial	–	$1.31M	2	2026-07-16	63,940
Iyengar Vijay KEVP, GMAPPS	–	$1.19M	6	2025-07-16	40,540
Tray ThomasPrincipal Accounting Officer	–	$1.08M	10	2026-06-04	21,132
Heeson LeeEVP, Head of Incyte Intl	–	$289,017	1	2025-11-03	29,241

Open-market purchases and sales

Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.

Date	Insider	Trade	Shares	Price	Value	Holds after	Filing
2026-09-15	Cagnoni Pablo JPresident, Global Head of R&D	Saleplan	9,233	120.50	$1.11M	197,185	Form 4
2026-09-15	Cagnoni Pablo JPresident, Global Head of R&D	Saleplan	13,985	120.49	$1.69M	183,200	Form 4
2026-08-19	Cagnoni Pablo JPresident, Global Head of R&D	Saleplan	10,801	125.56	$1.36M	183,200	Form 4
2026-08-12	Cagnoni Pablo JPresident, Global Head of R&D	Saleplan	10,803	120.04	$1.30M	194,001	Form 4
2026-08-05	Cagnoni Pablo JPresident, Global Head of R&D	Saleplan	10,640	122.69	$1.31M	204,804	Form 4
2026-08-05	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	2,207	123.99	$273,646	61,441	Form 4
2026-08-03	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	6,055	120.43	$729,204	61,441	Form 4
2026-07-31	Cagnoni Pablo JPresident, Global Head of R&D	Saleplan	15,888	119.70	$1.90M	215,444	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	14,661	119.46	$1.75M	88,679	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	5,332	119.42	$636,747	83,347	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	2,187	119.47	$261,281	81,160	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	6,171	119.43	$737,003	74,989	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	4,695	119.39	$560,536	70,294	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	2,864	119.40	$341,962	67,430	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	1,643	119.51	$196,355	65,787	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	1,642	119.38	$196,022	64,145	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	85	122.19	$10,386	64,060	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	326	121.69	$39,671	63,734	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	2,293	119.41	$273,807	61,441	Form 4
2026-07-16	Stein Steven HCMO & Head of Late-Stage Dev.	Saleplan	1,877	114.73	$215,348	21,118	Form 4
2026-07-16	Issa Mohamed KhairieEVP, Head of U.S. Commercial	Saleplan	1,093	115.01	$125,706	63,940	Form 4
2026-07-15	Stein Steven HCMO & Head of Late-Stage Dev.	Saleplan	28,237	113.05	$3.19M	26,083	Form 4
2026-06-04	Tray ThomasPrincipal Accounting Officer	Saleplan	2,639	100.00	$263,900	21,132	Form 4
2026-05-26	Tray ThomasPrincipal Accounting Officer	Saleplan	2,051	97.35	$199,665	21,132	Form 4
2026-05-19	Clancy Paul JDirector	Saleplan	15,000	94.93	$1.42M	23,741	Form 4
2026-04-17	Cagnoni Pablo JPresident, Global Head of R&D	Saleplan	18,667	96.50	$1.80M	262,692	Form 4
2026-03-17	Cagnoni Pablo JPresident, R&D	Saleplan	18,667	94.24	$1.76M	234,800	Form 4
2026-02-19	Cagnoni Pablo JPresident, R&D	Saleplan	18,668	100.91	$1.88M	234,800	Form 4
2026-01-07	Issa Mohamed KhairieEVP, Head of US Oncology	Saleplan	10,856	109.07	$1.18M	66,132	Form 4
2026-01-05	Stein Steven HEVP & Chief Medical Officer	Saleplan	15,634	101.70	$1.59M	34,203	Form 4
2025-12-19	Tray ThomasPrincipal Accounting Officer	Saleplan	2,774	100.00	$277,400	22,973	Form 4
2025-12-18	Tray ThomasPrincipal Accounting Officer	Saleplan	600	98.25	$58,950	22,973	Form 4
2025-12-17	Morrissey Michael JamesEVP, Head of Tech. Operations	Saleplan	4,323	97.26	$420,455	27,507	Form 4
2025-12-16	Morrissey Michael JamesEVP, Head of Tech. Operations	Saleplan	833	97.42	$81,151	85,005	Form 4
2025-12-16	Morrissey Michael JamesEVP, Head of Tech. Operations	Saleplan	53,175	97.29	$5.17M	31,830	Form 4
2025-12-11	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	255	94.94	$24,210	60,011	Form 4
2025-12-10	Mayes Patrick AEVP & Chief Scientific Officer	Saleplan	5,553	95.58	$530,756	60,266	Form 4
2025-12-02	Stein Steven HEVP & Chief Medical Officer	Saleplan	20,105	102.51	$2.06M	63,129	Form 4
2025-12-01	Stein Steven HEVP & Chief Medical Officer	Saleplan	2,559	102.96	$263,475	100,327	Form 4
2025-11-24	Tray ThomasPrincipal Accounting Officer	Saleplan	600	103.00	$61,800	23,573	Form 4

41 more

2025-11-21	Tray ThomasPrincipal Accounting Officer	Saleplan	169	102.00	$17,238	24,173	Form 4
2025-11-17	Denton Sheila A.EVP & General Counsel	Saleplan	278	104.36	$29,012	26,569	Form 4
2025-11-10	Hoppenot HerveDirector	Saleplan	187,500	105.46	$19.77M	329,646	Form 4
2025-11-05	Stein Steven HEVP & Chief Medical Officer	Saleplan	5,233	102.20	$534,813	102,886	Form 4
2025-11-04	Denton Sheila A.EVP & General Counsel	Saleplan	598	101.36	$60,613	26,569	Form 4
2025-11-03	Heeson LeeEVP, Head of Incyte Intl	Saleplan	3,074	94.02	$289,017	29,241	Form 4
2025-10-15	Denton Sheila A.EVP & General Counsel	Saleplan	277	85.13	$23,581	26,569	Form 4
2025-10-03	Denton Sheila A.EVP & General Counsel	Saleplan	3,501	85.54	$299,476	26,569	Form 4
2025-10-02	Denton Sheila A.EVP & General Counsel	Saleplan	599	87.65	$52,502	33,200	Form 4
2025-09-16	Denton Sheila A.EVP & General Counsel	Saleplan	278	83.15	$23,116	33,200	Form 4
2025-09-02	Denton Sheila A.EVP & General Counsel	Saleplan	598	84.97	$50,812	33,200	Form 4
2025-08-15	Denton Sheila A.EVP & General Counsel	Saleplan	277	86.81	$24,046	33,200	Form 4
2025-08-04	Denton Sheila A.EVP & General Counsel	Saleplan	598	75.77	$45,310	33,200	Form 4
2025-07-21	Stein Steven HEVP & Chief Medical Officer	Saleplan	3,706	67.94	$251,786	102,886	Form 4
2025-07-16	Denton Sheila A.EVP & General Counsel	Saleplan	785	68.36	$53,663	33,200	Form 4
2025-07-16	Iyengar Vijay KEVP, GMAPPS	Saleplan	983	68.36	$67,198	40,540	Form 4
2025-07-16	Flannelly Barry PEVP & General Manager US	Saleplan	1,340	68.36	$91,602	35,149	Form 4
2025-07-15	Denton Sheila A.EVP & General Counsel	Saleplan	3,330	69.86	$232,634	26,504	Form 4
2025-07-15	Flannelly Barry PEVP & General Manager US	Saleplan	1,192	69.86	$83,273	37,630	Form 4
2025-07-15	Iyengar Vijay KEVP, GMAPPS	Saleplan	1,177	69.86	$82,225	35,929	Form 4
2025-07-14	Stein Steven HEVP & Chief Medical Officer	Saleplan	14,952	68.47	$1.02M	97,466	Form 4
2025-07-03	Iyengar Vijay KEVP, GMAPPS	Saleplan	2,682	68.16	$182,805	43,636	Form 4
2025-07-03	Iyengar Vijay KEVP, GMAPPS	Saleplan	5,935	68.15	$404,470	37,701	Form 4
2025-07-03	Flannelly Barry PEVP & General Manager US	Saleplan	10,903	68.15	$743,039	39,744	Form 4
2025-07-02	Denton Sheila A.EVP & General Counsel	Saleplan	599	68.61	$41,097	26,504	Form 4
2025-06-03	Denton Sheila A.EVP & General Counsel	Saleplan	1,795	68.00	$122,060	26,504	Form 4
2025-06-02	Tray ThomasPrincipal Accounting Officer	Saleplan	651	64.88	$42,237	22,003	Form 4
2025-05-30	Tray ThomasPrincipal Accounting Officer	Saleplan	963	65.71	$63,279	22,654	Form 4
2025-03-14	Flannelly Barry PEVP & General Manager US	Saleplan	461	67.85	$31,279	52,913	Form 4
2025-03-14	Flannelly Barry PEVP & General Manager US	Saleplan	199	67.88	$13,508	52,714	Form 4
2025-03-14	Flannelly Barry PEVP & General Manager US	Saleplan	19,147	67.68	$1.30M	33,567	Form 4
2025-03-04	Denton Sheila A.EVP & General Counsel	Saleplan	599	69.99	$41,924	25,848	Form 4
2025-02-26	Denton Sheila A.EVP & General Counsel	Saleplan	9,574	74.07	$709,146	30,343	Form 4
2025-02-26	Denton Sheila A.EVP & General Counsel	Saleplan	4,495	74.08	$332,990	25,848	Form 4
2025-01-21	Stein Steven HEVP & Chief Medical Officer	Saleplan	12,352	72.69	$897,867	66,967	Form 4
2024-12-16	Tray ThomasPrincipal Accounting Officer	Saleplan	650	69.31	$45,052	23,312	Form 4
2024-12-13	Tray ThomasPrincipal Accounting Officer	Saleplan	650	70.64	$45,916	23,962	Form 4
2024-11-29	Iyengar Vijay KEVP, GMAPPS	Saleplan	360	75.60	$27,216	36,341	Form 4
2024-11-29	Iyengar Vijay KEVP, GMAPPS	Saleplan	5,683	75.37	$428,328	30,658	Form 4
2024-11-06	Flannelly Barry PEVP & General Manager US	Saleplan	1,424	82.00	$116,768	60,298	Form 4
2024-11-06	Flannelly Barry PEVP & General Manager US	Saleplan	2,256	78.21	$176,442	58,042	Form 4

Grants, exercises and other transactions

Pay, tax and paperwork rather than a choice to trade at the market price. Two years.

95 × grant or award65 × shares withheld for tax53 × option exercise

Show them

Date	Insider	What	Shares	Price	Holds after	Filing
2026-10-01	Heeson LeeEVP, Head of Incyte Intl	Shares withheld for tax F	−463	117.14	37,578	Form 4
2026-09-30	Harrigan EdmundDirector	Grant or award A	+206	121.35	23,225	Form 4
2026-09-30	Baker JulianDirector, 10% owner	Grant or award A	+322	–	2,835,403	Form 4
2026-09-30	Baker JulianDirector, 10% owner	Grant or award A	+322	–	28,206,082	Form 4
2026-09-30	Clancy Paul JDirector	Grant or award A	+203	121.35	25,838	Form 4
2026-09-22	Gardner David HEVP, Chief Strategy Officer	Shares withheld for tax F	−920	126.93	15,904	Form 4
2026-09-15	Cagnoni Pablo JPresident, Global Head of R&D	Option exercise M	+2,957	61.76	186,157	Form 4
2026-09-15	Cagnoni Pablo JPresident, Global Head of R&D	Option exercise M	+4,551	61.18	190,708	Form 4
2026-09-15	Cagnoni Pablo JPresident, Global Head of R&D	Option exercise M	+6,477	64.25	197,185	Form 4
2026-09-15	Cagnoni Pablo JPresident, Global Head of R&D	Option exercise M	+9,233	71.93	206,418	Form 4
2026-08-25	Basi Ramitpal KEVP, Human Resources	Shares withheld for tax F	−504	129.72	10,993	Form 4
2026-08-05	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+2,207	106.47	63,648	Form 4
2026-08-03	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+6,055	105.43	67,496	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+2,918	61.18	66,546	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+2,284	64.25	68,830	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+2,709	61.76	71,539	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+3,148	68.62	74,687	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+2,072	71.93	76,759	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+9,459	72.27	86,218	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+2,623	74.78	88,841	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+2,864	77.67	91,705	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+1,643	80.50	93,348	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+3,023	83.20	96,371	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+2,623	83.58	98,994	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+1,642	85.01	100,636	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+2,293	90.56	102,929	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+85	106.47	103,014	Form 4
2026-07-31	Mayes Patrick AEVP & Chief Scientific Officer	Option exercise M	+326	105.43	103,340	Form 4
2026-07-16	Cagnoni Pablo JPresident, Global Head of R&D	Grant or award A	+13,403	–	231,332	Form 4
2026-07-16	Meury WilliamDirector, Chief Executive Officer	Grant or award A	+26,807	–	183,129	Form 4
2026-07-16	Stein Steven HCMO & Head of Late-Stage Dev.	Grant or award A	+9,798	–	30,916	Form 4
2026-07-16	Tray ThomasPrincipal Accounting Officer	Grant or award A	+2,834	–	21,699	Form 4
2026-07-16	Issa Mohamed KhairieEVP, Head of U.S. Commercial	Grant or award A	+7,857	–	71,797	Form 4
2026-07-16	Mayes Patrick AEVP & Chief Scientific Officer	Grant or award A	+5,916	–	63,628	Form 4
2026-07-16	Basi Ramitpal KEVP, Human Resources	Grant or award A	+4,991	–	11,497	Form 4
2026-07-16	Gardner David HEVP, Chief Strategy Officer	Grant or award A	+7,395	–	16,824	Form 4
2026-07-16	Hoffman Richard A.EVP & General Counsel	Grant or award A	+7,395	–	16,861	Form 4
2026-07-15	Cagnoni Pablo JPresident, Global Head of R&D	Shares withheld for tax F	−4,950	115.09	217,929	Form 4
2026-07-15	Stein Steven HCMO & Head of Late-Stage Dev.	Shares withheld for tax F	−3,088	115.09	22,995	Form 4
2026-07-15	Tray ThomasPrincipal Accounting Officer	Shares withheld for tax F	−1,098	115.09	18,865	Form 4
2026-07-15	Issa Mohamed KhairieEVP, Head of U.S. Commercial	Shares withheld for tax F	−1,099	115.09	65,033	Form 4
2026-07-15	Mayes Patrick AEVP & Chief Scientific Officer	Shares withheld for tax F	−1,512	115.09	57,712	Form 4
2026-07-14	Cagnoni Pablo JPresident, Global Head of R&D	Shares withheld for tax F	−17,969	114.88	222,879	Form 4
2026-07-14	Stein Steven HCMO & Head of Late-Stage Dev.	Shares withheld for tax F	−21,830	114.88	54,320	Form 4
2026-07-14	Tray ThomasPrincipal Accounting Officer	Shares withheld for tax F	−692	114.88	19,963	Form 4
2026-07-14	Mayes Patrick AEVP & Chief Scientific Officer	Shares withheld for tax F	−437	114.88	59,224	Form 4
2026-07-02	Meury WilliamDirector, Chief Executive Officer, Other	Shares withheld for tax F	−4,779	116.86	156,322	Form 4
2026-07-02	Stein Steven HCMO & Head of Late-Stage Dev.	Shares withheld for tax F	−2,177	116.86	76,150	Form 4
2026-07-02	Tray ThomasPrincipal Accounting Officer	Shares withheld for tax F	−477	116.86	20,655	Form 4
2026-07-02	Mayes Patrick AEVP & Chief Scientific Officer	Shares withheld for tax F	−350	116.86	59,661	Form 4
2026-06-30	Harrigan EdmundDirector	Grant or award A	+255	113.36	23,019	Form 4
2026-06-30	Baker JulianDirector, 10% owner	Grant or award A	+400	–	2,835,081	Form 4
2026-06-30	Baker JulianDirector, 10% owner	Grant or award A	+400	–	28,205,760	Form 4
2026-06-30	Clancy Paul JDirector	Grant or award A	+252	113.36	25,635	Form 4
2026-06-08	Harrigan EdmundDirector	Grant or award A	+1,642	–	22,764	Form 4
2026-06-08	Baker JulianDirector, 10% owner	Grant or award A	+1,642	–	2,834,681	Form 4
2026-06-08	Baker JulianDirector, 10% owner	Grant or award A	+1,642	–	28,205,360	Form 4
2026-06-08	Brawley Otis WDirector	Grant or award A	+1,642	–	12,894	Form 4
2026-06-08	Bienaime Jean JacquesDirector	Grant or award A	+1,642	–	24,424	Form 4
2026-06-08	Fouse Jacqualyn ADirector	Grant or award A	+1,642	–	20,968	Form 4
2026-06-08	Clancy Paul JDirector	Grant or award A	+1,642	–	25,383	Form 4
2026-06-08	High Katherine ADirector	Grant or award A	+1,642	–	14,983	Form 4
2026-06-04	Tray ThomasPrincipal Accounting Officer	Option exercise M	+2,639	83.83	23,771	Form 4
2026-06-01	Cagnoni Pablo JPresident, Global Head of R&D	Shares withheld for tax F	−25,469	95.59	240,848	Form 4
2026-05-26	Bienaime Jean JacquesDirector	Option exercise M	+15,000	84.53	35,841	Form 4
2026-05-26	Bienaime Jean JacquesDirector	Shares withheld for tax F	−13,059	97.10	22,782	Form 4
2026-05-19	Clancy Paul JDirector	Option exercise M	+15,000	84.53	38,741	Form 4
2026-05-08	Baker JulianDirector, 10% owner	Option exercise M	+15,000	84.53	2,833,039	Form 4
2026-05-08	Baker JulianDirector, 10% owner	Option exercise M	+15,000	84.53	28,203,718	Form 4
2026-05-06	Cagnoni Pablo JPresident, Global Head of R&D	Grant or award A	+31,517	–	266,317	Form 4/A
2026-05-06	Stein Steven HCMO & Head of Late-Stage Dev.	Grant or award A	+44,124	–	78,327	Form 4/A
2026-05-04	Upadhyay SuketuEVP & Chief Financial Officer	Grant or award A	+26,343	–	26,343	Form 4
2026-04-17	Cagnoni Pablo JPresident, Global Head of R&D	Option exercise M	+6,077	64.25	268,769	Form 4
2026-04-17	Cagnoni Pablo JPresident, Global Head of R&D	Option exercise M	+12,590	71.93	281,359	Form 4
2026-04-15	Cagnoni Pablo JPresident, Global Head of R&D	Grant or award A	+27,892	–	262,692	Form 4
2026-04-15	Meury WilliamDirector, Chief Executive Officer, Other	Option exercise M	+125,000	–	161,101	Form 4
2026-04-15	Stein Steven HCMO & Head of Late-Stage Dev.	Grant or award A	+39,049	–	73,252	Form 4
2026-03-31	Harrigan EdmundDirector	Grant or award A	+269	94.12	21,122	Form 4
2026-03-31	Baker JulianDirector, 10% owner	Grant or award A	+421	–	2,818,039	Form 4
2026-03-31	Baker JulianDirector, 10% owner	Grant or award A	+421	–	28,188,718	Form 4
2026-03-31	Clancy Paul JDirector	Grant or award A	+265	94.12	23,741	Form 4
2026-03-25	Trotta MatteoEVP, GM, Dermatology US	Shares withheld for tax F	−537	92.23	14,882	Form 4
2026-03-17	Cagnoni Pablo JPresident, R&D	Option exercise M	+7,166	61.18	241,966	Form 4
2026-03-17	Cagnoni Pablo JPresident, R&D	Option exercise M	+11,501	64.25	253,467	Form 4
2026-02-19	Cagnoni Pablo JPresident, R&D	Option exercise M	+13,093	61.76	247,893	Form 4
2026-02-19	Cagnoni Pablo JPresident, R&D	Option exercise M	+5,575	61.18	253,468	Form 4
2026-02-02	Morrissey Michael JamesEVP, Head of Tech. Operations	Shares withheld for tax F	−185	102.67	34,065	Form 4
2026-02-02	Heeson LeeEVP, Head of Incyte Intl	Shares withheld for tax F	−111	102.67	38,041	Form 4
2026-01-20	Morrissey Michael JamesEVP, Head of Tech. Operations	Shares withheld for tax F	−429	102.62	34,250	Form 4
2026-01-16	Morrissey Michael JamesEVP, Head of Tech. Operations	Grant or award A	+7,426	–	34,679	Form 4
2026-01-16	Heeson LeeEVP, Head of Incyte Intl	Grant or award A	+8,911	–	38,152	Form 4
2026-01-06	Issa Mohamed KhairieEVP, Head of US Oncology	Shares withheld for tax F	−8,264	106.66	76,988	Form 4
2025-12-31	Harrigan EdmundDirector	Grant or award A	+245	98.77	20,853	Form 4
2025-12-31	Baker JulianDirector, 10% owner	Grant or award A	+328	–	2,817,618	Form 4
2025-12-31	Baker JulianDirector, 10% owner	Grant or award A	+328	–	28,188,297	Form 4
2025-12-31	Clancy Paul JDirector	Grant or award A	+241	98.77	23,476	Form 4
2025-12-31	Stein Steven HEVP & Chief Medical Officer	Shares withheld for tax F	−13,292	98.77	49,837	Form 4
2025-12-31	Morrissey Michael JamesEVP, Head of Tech. Operations	Shares withheld for tax F	−254	98.77	27,253	Form 4
2025-12-19	Tray ThomasPrincipal Accounting Officer	Option exercise M	+1,044	95.76	24,017	Form 4
2025-12-19	Tray ThomasPrincipal Accounting Officer	Option exercise M	+1,730	95.76	25,747	Form 4
2025-12-08	Hoppenot HerveDirector	Shares withheld for tax F	−2,843	96.70	326,803	Form 4
2025-12-01	Stein Steven HEVP & Chief Medical Officer	Shares withheld for tax F	−17,093	102.04	83,234	Form 4
2025-12-01	Morrissey Michael JamesEVP, Head of Tech. Operations	Shares withheld for tax F	−326	102.04	85,838	Form 4
2025-12-01	Hoffman Richard A.EVP & General Counsel	Grant or award A	+9,466	–	9,466	Form 4
2025-11-17	Denton Sheila A.EVP & General Counsel	Option exercise M	+278	64.25	26,847	Form 4
2025-11-05	Stein Steven HEVP & Chief Medical Officer	Option exercise M	+1,194	83.83	104,080	Form 4
2025-11-05	Stein Steven HEVP & Chief Medical Officer	Option exercise M	+2,995	95.76	107,075	Form 4
2025-11-05	Stein Steven HEVP & Chief Medical Officer	Option exercise M	+1,044	95.76	108,119	Form 4
2025-11-04	Denton Sheila A.EVP & General Counsel	Option exercise M	+598	58.06	27,167	Form 4
2025-10-15	Denton Sheila A.EVP & General Counsel	Option exercise M	+277	64.25	26,846	Form 4
2025-10-02	Denton Sheila A.EVP & General Counsel	Option exercise M	+599	58.06	33,799	Form 4
2025-10-02	Denton Sheila A.EVP & General Counsel	Shares withheld for tax F	−3,130	86.28	30,070	Form 4
2025-10-01	Heeson LeeEVP, Head of Incyte Intl	Shares withheld for tax F	−463	86.70	32,315	Form 4
2025-10-01	Mayes Patrick AEVP & Chief Scientific Officer	Shares withheld for tax F	−1,569	86.70	65,819	Form 4
2025-09-30	Harrigan EdmundDirector	Grant or award A	+289	84.81	20,608	Form 4
2025-09-30	Baker JulianDirector, 10% owner	Grant or award A	+388	–	2,817,290	Form 4
2025-09-30	Baker JulianDirector, 10% owner	Grant or award A	+388	–	28,187,969	Form 4
2025-09-30	Clancy Paul JDirector	Grant or award A	+285	84.81	23,235	Form 4
2025-09-22	Gardner David HEVP, Chief Strategy Officer	Grant or award A	+9,429	–	9,429	Form 4
2025-09-16	Denton Sheila A.EVP & General Counsel	Option exercise M	+278	64.25	33,478	Form 4
2025-09-02	Denton Sheila A.EVP & General Counsel	Option exercise M	+598	58.06	33,798	Form 4
2025-08-25	Basi Ramitpal KEVP, Human Resources	Grant or award A	+6,506	–	6,506	Form 4
2025-08-15	Denton Sheila A.EVP & General Counsel	Option exercise M	+277	64.25	33,477	Form 4
2025-08-04	Denton Sheila A.EVP & General Counsel	Option exercise M	+598	58.06	33,798	Form 4
2025-07-15	Trotta MatteoEVP, GM, Dermatology US	Shares withheld for tax F	−182	68.25	9,755	Form 4
2025-07-15	Trotta MatteoEVP, GM, Dermatology US	Grant or award A	+5,261	–	15,016	Form 4
2025-07-15	Issa Mohamed KhairieEVP, Head of US Oncology	Grant or award A	+8,769	–	85,252	Form 4
2025-07-15	Denton Sheila A.EVP & General Counsel	Option exercise M	+3,330	64.25	29,834	Form 4
2025-07-15	Denton Sheila A.EVP & General Counsel	Shares withheld for tax F	−703	68.25	25,801	Form 4
2025-07-15	Denton Sheila A.EVP & General Counsel	Grant or award A	+8,184	–	33,985	Form 4
2025-07-15	Hoppenot HerveDirector, Special Advisor to the CEO	Shares withheld for tax F	−4,713	68.25	517,146	Form 4
2025-07-15	Flannelly Barry PEVP & General Manager US	Shares withheld for tax F	−1,141	68.25	36,489	Form 4
2025-07-15	Iyengar Vijay KEVP, GMAPPS	Shares withheld for tax F	−836	68.25	35,093	Form 4
2025-07-15	Iyengar Vijay KEVP, GMAPPS	Grant or award A	+6,430	–	41,523	Form 4
2025-07-15	Tray ThomasPrincipal Accounting Officer	Shares withheld for tax F	−583	68.25	19,831	Form 4
2025-07-15	Tray ThomasPrincipal Accounting Officer	Grant or award A	+4,482	–	24,313	Form 4
2025-07-15	Stamoulis ChristianaEVP & Chief Financial Officer	Shares withheld for tax F	−1,445	68.25	114,652	Form 4
2025-07-15	Stamoulis ChristianaEVP & Chief Financial Officer	Grant or award A	+11,107	–	125,759	Form 4
2025-07-15	Swain Paula JEVP, Human Resources	Shares withheld for tax F	−563	68.25	100,052	Form 4
2025-07-15	Swain Paula JEVP, Human Resources	Grant or award A	+6,430	–	106,482	Form 4
2025-07-15	Stein Steven HEVP & Chief Medical Officer	Shares withheld for tax F	−1,596	68.25	94,315	Form 4
2025-07-15	Stein Steven HEVP & Chief Medical Officer	Grant or award A	+12,277	–	106,592	Form 4
2025-07-15	Cagnoni Pablo JPresident, R&D	Shares withheld for tax F	−2,628	68.25	217,262	Form 4
2025-07-15	Cagnoni Pablo JPresident, R&D	Grant or award A	+17,538	–	234,800	Form 4
2025-07-14	Hoppenot HerveDirector, Special Advisor to the CEO	Shares withheld for tax F	−4,961	69.98	521,859	Form 4
2025-07-14	Flannelly Barry PEVP & General Manager US	Shares withheld for tax F	−922	69.98	38,822	Form 4
2025-07-14	Iyengar Vijay KEVP, GMAPPS	Shares withheld for tax F	−595	69.98	37,106	Form 4
2025-07-14	Tray ThomasPrincipal Accounting Officer	Shares withheld for tax F	−692	69.98	20,414	Form 4
2025-07-14	Stamoulis ChristianaEVP & Chief Financial Officer	Shares withheld for tax F	−1,407	69.98	116,097	Form 4
2025-07-14	Swain Paula JEVP, Human Resources	Shares withheld for tax F	−444	69.98	100,615	Form 4
2025-07-14	Stein Steven HEVP & Chief Medical Officer	Shares withheld for tax F	−1,555	69.98	95,911	Form 4
2025-07-14	Cagnoni Pablo JPresident, R&D	Shares withheld for tax F	−1,280	69.98	219,890	Form 4
2025-07-02	Hoppenot HerveDirector, Special Advisor to the CEO	Shares withheld for tax F	−42,769	68.17	526,820	Form 4
2025-07-02	Iyengar Vijay KEVP, GMAPPS	Shares withheld for tax F	−6,809	68.17	46,318	Form 4
2025-07-02	Denton Sheila A.EVP & General Counsel	Option exercise M	+599	58.06	27,103	Form 4
2025-07-02	Flannelly Barry PEVP & General Manager US	Shares withheld for tax F	−9,055	68.17	50,647	Form 4
2025-07-02	Stamoulis ChristianaEVP & Chief Financial Officer	Shares withheld for tax F	−11,589	68.17	117,504	Form 4
2025-07-02	Stein Steven HEVP & Chief Medical Officer	Shares withheld for tax F	−12,714	68.17	112,418	Form 4
2025-07-02	Tray ThomasPrincipal Accounting Officer	Shares withheld for tax F	−897	68.17	21,106	Form 4
2025-07-02	Swain Paula JEVP, Human Resources	Shares withheld for tax F	−6,285	68.17	101,059	Form 4
2025-07-02	Meury WilliamDirector, Chief Executive Officer, Other	Grant or award A	+36,101	–	36,101	Form 4
2025-06-30	Issa Mohamed KhairieEVP, Head of US Oncology	Grant or award A	+27,812	–	76,483	Form 4
2025-06-30	Harrigan EdmundDirector	Grant or award A	+367	68.10	20,319	Form 4
2025-06-30	Clancy Paul JDirector	Grant or award A	+361	68.10	22,950	Form 4
2025-06-30	Baker JulianDirector, 10% owner	Grant or award A	+492	–	2,816,902	Form 4
2025-06-30	Baker JulianDirector, 10% owner	Grant or award A	+492	–	28,187,581	Form 4
2025-06-26	Hoppenot HerveDirector, Special Advisor to the CEO	Grant or award A	+6,016	–	569,589	Form 4
2025-06-10	Baker JulianDirector, 10% owner	Grant or award A	+2,518	–	2,816,410	Form 4
2025-06-10	Baker JulianDirector, 10% owner	Grant or award A	+2,518	–	28,187,089	Form 4
2025-06-10	Harrigan EdmundDirector	Grant or award A	+2,518	–	19,952	Form 4
2025-06-10	Schaffert SusanneDirector	Shares withheld for tax F	−849	70.07	4,871	Form 4
2025-06-10	Schaffert SusanneDirector	Grant or award A	+2,518	–	7,389	Form 4
2025-06-10	Clancy Paul JDirector	Grant or award A	+2,518	–	22,589	Form 4
2025-06-10	High Katherine ADirector	Grant or award A	+2,518	–	13,341	Form 4
2025-06-10	Bienaime Jean JacquesDirector	Grant or award A	+2,518	–	20,841	Form 4
2025-06-10	Fouse Jacqualyn ADirector	Grant or award A	+2,518	–	19,326	Form 4
2025-06-10	Brawley Otis WDirector	Grant or award A	+2,518	–	11,252	Form 4
2025-06-03	Denton Sheila A.EVP & General Counsel	Option exercise M	+1,795	58.06	28,299	Form 4
2025-04-01	Hoppenot HerveDirector, Chairman / CEO, Other	Grant or award A	+66,899	–	563,573	Form 4
2025-04-01	Swain Paula JEVP, Human Resources	Grant or award A	+11,159	–	96,362	Form 4
2025-04-01	Swain Paula JEVP, Human Resources	Grant or award A	+10,982	–	107,344	Form 4
2025-04-01	Stein Steven HEVP & Chief Medical Officer	Grant or award A	+37,198	–	104,165	Form 4
2025-04-01	Stein Steven HEVP & Chief Medical Officer	Grant or award A	+20,967	–	125,132	Form 4
2025-04-01	Stamoulis ChristianaEVP & Chief Financial Officer	Grant or award A	+18,598	–	110,123	Form 4
2025-04-01	Stamoulis ChristianaEVP & Chief Financial Officer	Grant or award A	+18,970	–	129,093	Form 4
2025-04-01	Morrissey Michael JamesEVP, Head of Tech. Operations	Grant or award A	+4,649	–	86,164	Form 4
2025-04-01	Iyengar Vijay KEVP, GMAPPS	Grant or award A	+11,159	–	41,817	Form 4
2025-04-01	Iyengar Vijay KEVP, GMAPPS	Grant or award A	+10,982	–	52,799	Form 4
2025-04-01	Flannelly Barry PEVP & General Manager US	Grant or award A	+11,159	–	44,726	Form 4
2025-04-01	Flannelly Barry PEVP & General Manager US	Grant or award A	+14,976	–	59,702	Form 4
2025-03-31	Baker JulianDirector, 10% owner	Grant or award A	+487	–	2,813,892	Form 4
2025-03-31	Baker JulianDirector, 10% owner	Grant or award A	+487	–	28,184,571	Form 4
2025-03-31	Harrigan EdmundDirector	Grant or award A	+363	60.55	17,434	Form 4
2025-03-31	Clancy Paul JDirector	Grant or award A	+358	60.55	20,071	Form 4
2025-03-25	Trotta MatteoEVP, GM, Dermatology US	Shares withheld for tax F	−537	62.08	9,937	Form 4
2025-03-04	Denton Sheila A.EVP & General Counsel	Option exercise M	+599	58.06	26,447	Form 4
2025-02-26	Denton Sheila A.EVP & General Counsel	Option exercise M	+9,574	58.06	39,917	Form 4
2025-01-31	Heeson LeeEVP, Head of Incyte Intl	Grant or award A	+6,331	–	32,778	Form 4
2025-01-31	Morrissey Michael JamesEVP, Head of Tech. Operations	Grant or award A	+10,552	–	81,515	Form 4
2025-01-21	Morrissey Michael JamesEVP, Head of Tech. Operations	Shares withheld for tax F	−429	73.47	70,963	Form 4

How to read it

Buy, sale: Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
Plan: A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
Holds after: The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
Value: Shares times the price the form reports, which is often an average over several fills on the day.

Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.

Incyte's scores and multiples ›